PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents yoy growth below half of AVXL's 9483.91%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Below half of AVXL's 9483.91%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
Below half of AVXL's 6099.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
835.01%
Below half AVXL's -8.99%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
Below half of AVXL's 50039.77%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Below half of AVXL's 6721.34%. Michael Burry sees a potential red flag for stagnation or capital shortage.
69.91%
Above 1.5x AVXL's 4.68%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-41.82%
Above 1.5x AVXL's -3.32%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Exceeding 1.5x AVXL's -19.60%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-44.50%
Less than half of AVXL's 3.41%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Less than half of AVXL's 3.47%. David Dodd sees far fewer liability expansions relative to competitor.
7.98%
Above 1.5x AVXL's 1.65%. Michael Burry suspects heavy new equity expansion or dilution.
4.22%
Below half AVXL's -2.49%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Above 1.5x AVXL's -100.00%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
132.15%
Below half AVXL's 603.41%. Michael Burry sees potential underperformance in building shareholder capital.
135.47%
Below half AVXL's 6721.34%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Above 1.5x AVXL's -2.81%. Michael Burry sees a major jump. Investigate leverage rationale.
-152.72%
Less than half of AVXL's -8716.51%. David Dodd sees better deleveraging or stronger cash buildup than competitor.